Effect of metallo-[beta]-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosabloodstream infection: a retrospective cohort study

• Published in: BMC infectious diseases 2013-11, Vol.13
• Main Authors: Willmann, Matthias, Kuebart, Ines, Marschal, Matthias, Schröppel, Klaus, Vogel, Wichard, Flesch, Ingo, Markert, Uwe, Autenrieth, Ingo B, Hölzl, Florian, Peter, Silke
• Format: Article
• Language: English
• Subjects: Beta lactamases; Drug resistance in microorganisms; Drug therapy; Germany; Health aspects; Mortality; Pseudomonas aeruginosa infections
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/1471-2334-13-515

Blood stream infections (BSI) with Pseudomonas aeruginosa lead to poor clinical outcomes. The worldwide emergence and spread of metallo-[beta]-lactamase (MBL) producing, often multidrug-resistant organisms may further aggravate this problem. Our study aimed to investigate the effect of MBL-producing P. aeruginosa (MBL-PA) and various other resistance phenotypes on clinical outcomes. A retrospective cohort study was conducted in three German hospitals. Medical files from 2006 until 2012 were studied, and a number of 113 patients with P. aeruginosa BSI were included. The presence of VIM, IMP and NDM genes was detected using molecular techniques. Genetic relatedness was assessed through multilocus sequence typing (MLST). The effect of resistance patterns or MBL production on clinical outcomes was investigated by using multivariate Cox regression models. In-hospital mortality was significantly higher in patients with MBL-PA and multidrug-resistant P. aeruginosa. However, neither BSI with MBL-PA nor BSI with various resistance phenotypes of P. aeruginosa were independently associated with mortality or length of hospital stay. In multivariate models, the SAPS II score (HR 1.046), appropriate definitive treatment (HR range 0.25-0.26), and cardiovascular disease (HR range 0.44-0.46) were independent predictors of mortality. Concomitant infections were associated with an excess length of stay (HR < 1). Medication with appropriate antimicrobial agents at any time during the course of infection remains the key for improving clinical outcomes in patients with P. aeruginosa BSI and should be combined with a strict implementation of routine infection control measures.